RXR–Thyroid Hormone Combinations for Remyelination and Neuroprotection

Solution Overview

Problem

Current treatments for nervous system disorders, such as multiple sclerosis, primarily focus on immunomodulation but fail to reverse pathology or restore neurological function by promoting remyelination and neuroprotection.

Innovation Solution

Administering a combination of a Retinoid X Receptor (RXR) agonist, such as IRX4204, and a thyroid hormone, like thyroxine, to induce remyelination, neuroprotection, and immunomodulation, thereby promoting the differentiation of suppressive Treg cells and inhibiting pro-inflammatory Th17 cells.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Duration of action of stationary object

If anti-inflammatory and immunomodulatory drugs are used to treat nervous system disorders, then disease progression is delayed, but neurological function cannot be restored and pathology cannot be reversed

Engineering Contradiction:

Improvedisease progression delayVSAvoidneurological function restoration

Core Design Contradiction:

Duration of action of stationary objectVSReliability

Solution Approach 1:

The patent combines two distinct therapeutic approaches: immunomodulation (to delay disease progression) and remyelination/neuroprotection (to restore neurological function). This is achieved by using compounds that simultaneously exhibit both immunomodulatory and remyelinating properties, or by combining separate agents that target both pathways, thereby resolving the contradiction between delaying progression and restoring function

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The patent identifies and utilizes compounds with multi-functional properties that can simultaneously modulate immune responses and promote remyelination. These compounds serve multiple therapeutic functions within a single treatment regimen, addressing both the need to delay disease progression and to restore neurological function without requiring separate specialized treatments

Inventive Principle:

Principle #6Universality (Multi-functionality)

2Ease of operation

If single-agent therapy is used, then treatment simplicity is maintained, but therapeutic efficacy is limited compared to combination therapy

Engineering Contradiction:

Improvetreatment simplicityVSAvoidtherapeutic efficacy

Core Design Contradiction:

Ease of operationVSReliability

Solution Approach 1:

The patent combines two distinct therapeutic approaches: immunomodulation (to delay disease progression) and remyelination/neuroprotection (to restore neurological function). This is achieved by using compounds that simultaneously exhibit both immunomodulatory and remyelinating properties, or by combining separate agents that target both pathways, thereby resolving the contradiction between delaying progression and restoring function

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The patent identifies and utilizes compounds with multi-functional properties that can simultaneously modulate immune responses and promote remyelination. These compounds serve multiple therapeutic functions within a single treatment regimen, addressing both the need to delay disease progression and to restore neurological function without requiring separate specialized treatments

Inventive Principle:

Principle #6Universality (Multi-functionality)

Data Source

PatentUS20250248962A1Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones

Publication Date: 2025.08.07 IO THERAPEUTICS INC

AI summary

Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone.